These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 1422319)

  • 1. Short-term treatment of Paget's disease of bone with ipriflavone.
    Agnusdei D; Camporeale A; Gonnelli S; Gennari C; Baroni MC; Passeri M
    Bone Miner; 1992 Oct; 19 Suppl 1():S35-42. PubMed ID: 1422319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study.
    Reginster JY; Colson F; Morlock G; Combe B; Ethgen D; Geusens P
    Arthritis Rheum; 1992 Aug; 35(8):967-74. PubMed ID: 1642662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The methodology of clinical trials of oral tiludronate in Paget's disease of bone.
    Roux C
    Bone; 1995 Nov; 17(5 Suppl):497S-499S. PubMed ID: 8573426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline:creatinine ratio in patients with Paget's disease of bone.
    Kaddam IM; Iqbal SJ; Holland S; Wong M; Manning D
    Ann Clin Biochem; 1994 Jul; 31 ( Pt 4)():327-30. PubMed ID: 7979096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aminohexane diphosphonate in the treatment of Paget's disease of bone.
    Atkins RM; Yates AJ; Gray RE; Urwin GH; Hamdy NA; Beneton MN; Rosini S; Kanis JA
    J Bone Miner Res; 1987 Aug; 2(4):273-9. PubMed ID: 3455614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paget's disease of bone: reduction of disease activity with oral risedronate.
    Hosking DJ; Eusebio RA; Chines AA
    Bone; 1998 Jan; 22(1):51-5. PubMed ID: 9437513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial.
    Reid IR; Nicholson GC; Weinstein RS; Hosking DJ; Cundy T; Kotowicz MA; Murphy WA; Yeap S; Dufresne S; Lombardi A; Musliner TA; Thompson DE; Yates AJ
    Am J Med; 1996 Oct; 101(4):341-8. PubMed ID: 8873503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of prolonged thyrocalcitonin administration on Paget's disease of bone.
    Haddad JG; Birge SJ; Avioli LV
    N Engl J Med; 1970 Sep; 283(11):549-55. PubMed ID: 5450609
    [No Abstract]   [Full Text] [Related]  

  • 9. Biochemical markers of bone turnover in Paget's disease of bone.
    Eastell R
    Bone; 1999 May; 24(5 Suppl):49S-50S. PubMed ID: 10321928
    [No Abstract]   [Full Text] [Related]  

  • 10. Paget's disease of bone treated with a five day course of oral tiludronate.
    Reginster JY; Lecart MP; Deroisy R; Ethgen D; Zegels B; Franchimont P
    Ann Rheum Dis; 1993 Jan; 52(1):54-7. PubMed ID: 8427515
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcitonin nasal spray for Paget's disease of the bone].
    Luboshitzky R; Bar-Shalom R
    Harefuah; 1995 Mar; 128(6):358-62, 399. PubMed ID: 7750816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of disodium dichloromethylene diphosphonate on Paget's disease of bone.
    Meunier PJ; Chapuy MC; Alexandre C; Bressot C; Edouard C; Vignon C; Mathieu L; Trechsel U
    Lancet; 1979 Sep; 2(8141):489-92. PubMed ID: 90215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pamidronate is effective for Paget's disease of bone refractory to conventional therapy.
    Wimalawansa SJ; Gunasekera RD
    Calcif Tissue Int; 1993 Oct; 53(4):237-41. PubMed ID: 8275351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of nasal hCT on bone turnover in Paget's disease of bone--implications for the treatment of other metabolic bone diseases.
    Reginster JY; Jeugmans-Huynen AM; Wouters M; Sarlet N; McIntyre HD; Franchimont P
    Br J Rheumatol; 1992 Jan; 31(1):35-9. PubMed ID: 1730104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of skeletal uptake of 99mTc-diphosphonate and alkaline phosphatase before and after oral diphosphonate therapy in Paget's disease.
    Smith ML; Fogelman I; Ralston S; Boyce BF; Boyle IT
    Metab Bone Dis Relat Res; 1984; 5(4):167-70. PubMed ID: 6429474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical markers of bone turnover in Paget's disease.
    Russell RG; Beard DJ; Cameron EC; Douglas DL; Forrest AR; Guilland-Cumming D; Paterson AD; Poser J; Preston CJ; Milford-Ward A; Woodhead S; Kanis JA
    Metab Bone Dis Relat Res; 1981; 3(4-5):255-62. PubMed ID: 6220191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variable efficacy of bone remodeling biochemical markers in the management of patients with Paget's disease of bone treated with tiludronate.
    de la Piedra C; Rapado A; Díaz Diego EM; Díaz Martín MA; Aguirre C; López Gavilanes E; Díaz Curiel M
    Calcif Tissue Int; 1996 Aug; 59(2):95-9. PubMed ID: 8687976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans).
    Altman RD; Johnston CC; Khairi MR; Wellman H; Serafini AN; Sankey RR
    N Engl J Med; 1973 Dec; 289(26):1379-84. PubMed ID: 4201876
    [No Abstract]   [Full Text] [Related]  

  • 19. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).
    Harinck HI; Papapoulos SE; Blanksma HJ; Moolenaar AJ; Vermeij P; Bijvoet OL
    Br Med J (Clin Res Ed); 1987 Nov; 295(6609):1301-5. PubMed ID: 3120987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Paget's disease: the prospects with ipriflavone].
    Bisbocci D; Gallo V; Damiano P; Cantoni R; Suriano A; Chiandussi L
    Recenti Prog Med; 1992 Dec; 83(12):701-6. PubMed ID: 1494710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.